{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:32:04Z","timestamp":1786375924271,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10928-026-10047-6","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:35:07Z","timestamp":1781692507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing heavy-tailed residual error models for outlier handling in population PK modeling"],"prefix":"10.1007","volume":"53","author":[{"given":"Yiming","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"2","key":"10047_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10928-015-9460-y","volume":"43","author":"AG Dosne","year":"2016","unstructured":"Dosne AG, Bergstrand M, Karlsson MO (2016) A strategy for residual error modeling incorporating scedasticity of variance and distribution shape. J Pharmacokinet Pharmacodyn 43(2):137\u2013151. https:\/\/doi.org\/10.1007\/s10928-015-9460-y","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"10047_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/pst.1598","volume":"13","author":"R De la Cruz","year":"2014","unstructured":"De la Cruz R (2014) Bayesian analysis for nonlinear mixed-effects models under heavy-tailed distributions. Pharm Stat 13(1):81\u201393. https:\/\/doi.org\/10.1002\/pst.1598","journal-title":"Pharm Stat"},{"issue":"1","key":"10047_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82(1):17\u201320. https:\/\/doi.org\/10.1038\/sj.clpt.6100241","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10047_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10928-011-9211-7","volume":"38","author":"L Choi","year":"2011","unstructured":"Choi L, Caffo BS, Kohli U, Pandharipande P, Kurnik D, Ely EW, Stein CM (2011) A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study. J Pharmacokinet Pharmacodyn 38(5):613\u2013636. https:\/\/doi.org\/10.1007\/s10928-011-9211-7","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10047_CR5","doi-asserted-by":"crossref","unstructured":"Rousseeuw Peter JLAM (1987) Robust Regression and Outlier Detection. Wiley","DOI":"10.1002\/0471725382"},{"issue":"9","key":"10047_CR6","doi-asserted-by":"publisher","first-page":"103925","DOI":"10.1016\/j.xphs.2025.103925","volume":"114","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Hu H, Ogasawara K, Li Y (2025) Integrative population pharmacokinetic modeling of two BCMA-targeted and one CD19-targeted CAR-T therapies using full Bayesian inference with a student\u2019s t-based M3 censoring approach for robust handling of outliers and BLQ data. J Pharm Sci 114(9):103925. https:\/\/doi.org\/10.1016\/j.xphs.2025.103925","journal-title":"J Pharm Sci"},{"issue":"7","key":"10047_CR7","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jcph.2426","volume":"64","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Du S, Hu H, Wang X, Carayannopoulos L, Li Y (2024) Integrating full bayesian inference and student\u2019s t-distribution method for enhanced outlier handling in caffeine population pharmacokinetics: assessing drug-drug interactions with enasidenib in relapsed or refractory AML and MDS patients. J Clin Pharmacol 64(7):866\u2013877. https:\/\/doi.org\/10.1002\/jcph.2426","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10047_CR8","doi-asserted-by":"publisher","first-page":"103916","DOI":"10.1016\/j.xphs.2025.103916","volume":"114","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Li Y (2025) Enhancing pharmacometric modeling with full Bayesian inference and Student\u2019s t-Based M3 Censoring: A simulated population PK study on robust handling of outliers and censored data. J Pharm Sci 114(9):103916. https:\/\/doi.org\/10.1016\/j.xphs.2025.103916","journal-title":"J Pharm Sci"},{"issue":"6","key":"10047_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1158\/1078-0432.CCR-24-2753","volume":"31","author":"H Hu","year":"2025","unstructured":"Hu H, Li Y, Piasecki J, Hosseyni D, Yan Z, Liu X, Ogasawara K, Zhou S, Cheng Y (2025) Population pharmacokinetics of orvacabtagene autoleucel, an autologous BCMA-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory multiple myeloma. Clin Cancer Res 31(6):1163\u20131171. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2753","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10047_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1208\/s12248-019-0305-2","volume":"21","author":"MMA Ibrahim","year":"2019","unstructured":"Ibrahim MMA, Ueckert S, Freiberga S, Kjellsson MC, Karlsson MO (2019) Model-based conditional weighted residuals analysis for structural model assessment. AAPS J 21(3):34. https:\/\/doi.org\/10.1208\/s12248-019-0305-2","journal-title":"AAPS J"},{"key":"10047_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/CPAA.S310604","volume":"13","author":"Y Cheng","year":"2021","unstructured":"ChengY, Chen J, Pourdehnad M, Zhou S, Li Y (2021) Population pharmacokinetics of CC-122. Clin Pharmacol 13:61\u201371. https:\/\/doi.org\/10.2147\/CPAA.S310604","journal-title":"Clin Pharmacol"},{"key":"10047_CR12","doi-asserted-by":"publisher","first-page":"617122","DOI":"10.3389\/fphar.2020.617122","volume":"11","author":"XD Guan","year":"2020","unstructured":"Guan XD, Tang XG, Zhang YJ, Xie HM, Luo L, Wu D, Chen R, Hu P (2020) Population pharmacokinetic analysis of yimitasvir in Chinese healthy volunteers and patients with chronic hepatitis C virus infection. Front Pharmacol 11:617122. https:\/\/doi.org\/10.3389\/fphar.2020.617122","journal-title":"Front Pharmacol"},{"issue":"5","key":"10047_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/bcp.13873","volume":"85","author":"JH Hughes","year":"2019","unstructured":"Hughes JH, Phelps MA, Upton RN, Reuter SE, Gao Y, Byrd JC, Grever MR, Hofmeister CC, Marcucci G, Blum W, Blum KA, Foster DJR (2019) Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. Br J Clin Pharmacol 85(5):924\u2013934. https:\/\/doi.org\/10.1111\/bcp.13873","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10047_CR14","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/bcp.15566","volume":"89","author":"R Kirubakaran","year":"2023","unstructured":"Kirubakaran R, Uster DW, Hennig S, Carland JE, Day RO, Wicha SG, Stocker SL (2023) Adaptation of a population pharmacokinetic model to inform tacrolimus therapy in heart transplant recipients. Br J Clin Pharmacol 89(3):1162\u20131175. https:\/\/doi.org\/10.1111\/bcp.15566","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10047_CR15","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40262-021-01039-5","volume":"60","author":"K Ogasawara","year":"2021","unstructured":"Ogasawara K, Dodds M, Mack T, Lymp J, Dell\u2019Aringa J, Smith J (2021) Population cellular kinetics of lisocabtagene maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory large B-cell lymphoma. Clin Pharmacokinet 60(12):1621\u20131633. https:\/\/doi.org\/10.1007\/s40262-021-01039-5","journal-title":"Clin Pharmacokinet"},{"key":"10047_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-025-01566-5","author":"L Schlachter","year":"2025","unstructured":"Schlachter L, Stodtmann S, Voelkner A, Jonsson F, Lagraauw HM, Boinpally RR (2025) Population pharmacokinetics of atogepant for the prevention of migraine. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-025-01566-5","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10047_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jcph.2380","volume":"64","author":"T Takeuchi","year":"2024","unstructured":"Takeuchi T, Chino Y, Mano Y, Kawanishi M, Sato Y, Uchida S, Tanaka Y (2024) Population pharmacokinetics of ozoralizumab in patients with rheumatoid Arthritis. J Clin Pharmacol 64(4):418\u2013427. https:\/\/doi.org\/10.1002\/jcph.2380","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10047_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s13318-021-00671-7","volume":"46","author":"E Wang","year":"2021","unstructured":"Wang E, DuBois SG, Wetmore C, Verschuur AC, Khosravan R (2021) Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. Eur J Drug Metab Pharmacokinet 46(3):343\u2013352. https:\/\/doi.org\/10.1007\/s13318-021-00671-7","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"10047_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/jcph.1733","volume":"61","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Patel YT, Fiedler-Kelly J, Feng HP, Bruno CJ, Gao W (2021) Population pharmacokinetic analysis for plasma and epithelial lining fluid ceftolozane\/tazobactam concentrations in patients with ventilated nosocomial pneumonia. J Clin Pharmacol 61(2):254\u2013268. https:\/\/doi.org\/10.1002\/jcph.1733","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10047_CR20","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s40262-023-01296-6","volume":"62","author":"S Baklouti","year":"2023","unstructured":"Baklouti S, Comets E, Gandia P, Concordet D (2023) Multivariate exact discrepancy: a new tool for PK\/PD model evaluation. Clin Pharmacokinet 62(11):1599\u20131609. https:\/\/doi.org\/10.1007\/s40262-023-01296-6","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10047_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"TH Nguyen","year":"2017","unstructured":"Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, John J, Karlsson MO, Mould DR, Perez Ruixo JJ, Plan EL, Savic R, van Hasselt JG, Weber B, Zhou C, Comets E, Mentre F, Model Evaluation Group of the International Society of Pharmacometrics Best Practice C (2017) Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst Pharmacol 6(2):87\u2013109. https:\/\/doi.org\/10.1002\/psp4.12161","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10047_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10928-007-9082-0","volume":"35","author":"N Semmar","year":"2008","unstructured":"Semmar N, Urien S, Bruguerolle B, Simon N (2008) Independent-model diagnostics for a priori identification and interpretation of outliers from a full pharmacokinetic database: correspondence analysis, Mahalanobis distance and Andrews curves. J Pharmacokinet Pharmacodyn 35(2):159\u2013183. https:\/\/doi.org\/10.1007\/s10928-007-9082-0","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"10047_CR23","doi-asserted-by":"publisher","first-page":"e2100302","DOI":"10.1002\/bimj.202100302","volume":"65","author":"LL Hernandez-Velasco","year":"2023","unstructured":"Hernandez-Velasco LL, Abanto-Valle CA, Dey DK, Castro LM (2023) A Bayesian approach for mixed effects state-space models under skewness and heavy tails. Biom J 65(8):e2100302. https:\/\/doi.org\/10.1002\/bimj.202100302","journal-title":"Biom J"},{"issue":"1","key":"10047_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11222-010-9212-1","volume":"22","author":"C Meza","year":"2012","unstructured":"Meza C, Osorio F, De la Cruz R (2012) Estimation in nonlinear mixed-effects models using heavy-tailed distributions. Stat Comput 22(1):121\u2013139. https:\/\/doi.org\/10.1007\/s11222-010-9212-1","journal-title":"Stat Comput"},{"key":"10047_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.csda.2013.06.022","volume":"71","author":"Weixing Song; Weixin Yao; Yanru Xing","year":"2014","unstructured":"Weixing Song; Weixin Yao; Yanru Xing (2014) Robust mixture regression model fitting by Laplace distribution. Comput Stat Data Anal 71:128\u2013137. https:\/\/doi.org\/10.1016\/j.csda.2013.06.022","journal-title":"Comput Stat Data Anal"},{"issue":"408","key":"10047_CR26","first-page":"881","volume":"84","author":"KL Lange","year":"1989","unstructured":"Lange KL et al (1989) Robust statistical modeling using the t distribution. J Am Stat Assoc 84(408):881\u2013896","journal-title":"J Am Stat Assoc"},{"key":"10047_CR27","unstructured":"Johnson Norman L, KS, Balakrishnan N (1994) Continuous univariate distributions, Volume 1, 2nd Edition"},{"key":"10047_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/9781118033197","author":"EP Box George","year":"1973","unstructured":"Box George EP TGC (1973) Bayesian inference in statistical analysis. Wiley. https:\/\/doi.org\/10.1002\/9781118033197","journal-title":"Wiley"},{"key":"10047_CR29","unstructured":"Population Pharmacokinetics Guidance for Industry (Food and Drug Administration) (2022)"},{"issue":"4","key":"10047_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/bimj.200900310","volume":"52","author":"M Bottai","year":"2010","unstructured":"Bottai M, Zhang J (2010) Laplace regression with censored data. Biom J 52(4):487\u2013503. https:\/\/doi.org\/10.1002\/bimj.200900310","journal-title":"Biom J"},{"key":"10047_CR31","doi-asserted-by":"publisher","unstructured":"Pinheiro Jos\u00e9 CLC, Wu Y Nian (2001) Efficient algorithms for robust estimation in linear mixed-effects models using the multivariate t distribution. J Comput Graphical Stat 10(2). https:\/\/doi.org\/10.1198\/10618600152628059","DOI":"10.1198\/10618600152628059"},{"issue":"3","key":"10047_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558\u2013569. https:\/\/doi.org\/10.1208\/s12248-009-9133-0","journal-title":"AAPS J"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10047-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10047-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10047-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:25:55Z","timestamp":1786375555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-026-10047-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10047"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10047-6","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors have reviewed and concurred with the manuscript.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.C. and Y.L. are employees and hold equity ownership in Bristol Myers Squibb.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31"}}